Worldwide increases in life expectancy have been paralleled by a greater prevalence of chronic and age-associated disorders, particularly of the cardiovascular, neural and metabolic systems. Patient-specific induced pluripotent stem (iPS) cells are finding applications in disease modelling, drug testing and drug discovery, thus enabling researchers to undertake studies for treating diseases 'in a dish'.
- Milena Bellin
- Maria C. Marchetto
- Christine L. Mummery